S100A10 as a novel biomarker in colorectal cancer

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3785-3790

  Shang, Jinfu ^a   Zhang, Zhanxue ^b   Song, Weiqing ^b   Zhou, Baojun ^b   Zhang, Yuesheng ^a   Li, Guixin ^b   Qiu, Shaofan ^b  

^a Medical Department The Second Central Hospital of Baoding City   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Colorectal cancer; Prognosis; S100A10

Indexed keywords

BIOLOGICAL MARKER; S100A10 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; S100A10 GENE;

EID: 84891486498     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0962-1     Document Type: Article

References (18)

1. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540-51.
2. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34:357-64.
3. Kwon M, Caplan JF, Filipenko NR, et al. Identification of annexin II heterotetramer as a plasmin reductase. J Biol Chem. 2002;2156:10903-11.
4. Hildenbrand R, Allgayer H, Marx A, Stroebel P. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs. 2010;19:641-52.
5. Ito Y, Arai K, Nozawa R, et al. S100A10 positivity in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res. 2007;27:2679-83.
6. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumor Biol. 2011;32:441-50.
7. Teratani T, Watanabe T, Kuwahara F, et al. Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. Cancer Lett. 2002;175:71-7.
8. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62:6823-6.
9. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, et al. Prognostic significance and molecular relationships of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19:1944-53.
10. Giovannucci E, Fuchs CS, Ogino S. Relationship of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305:1685-94.
11. Choi KS, Fogg DK, Yoon CS, Waisman DM. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J. 2003;17:235-46.
12. Madureira PA, O'Connell PA, Surette AP, Miller VA, Waisman DM. The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis. J Biomed Biotechnol. 2012;2012:353687.
13. Zhang L, Fogg DK, Waisman DM. RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. J Biol Chem. 2004;279:2053-62.
14. Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 2007;98:77-82.
15. Tan Y, Ma SY, Wang FQ, Meng HP, Mei C, Liu A, et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep. 2011;26:853-9.
16. Masiakowski P, Shooter EM. Changes in PC12 cell morphology induced by transfection with 42C cDNA, coding for a member of the S-100 protein family. J Neurosci Res. 1990;27:264-9.
17. Li Q, Laumonnier Y, Syrovets T, Simmet T. Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 2007;27:1383-9.
18. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colorectal cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491-501.